Cargando…

PB2393: ACTIVATION OF ER STRESS AND UNFOLDED PROTEIN RESPONSE (UPR) PATHWAYS IN HEPATITIS B VIRUS (HBV) INFECTED B CELLS AND ITS SIGNIFICANCE IN PATHOGENESIS OF B-CELL NON-HODGKIN LYMPHOMAS (B-NHL)

Detalles Bibliográficos
Autores principales:	Uta, Mihaela, Ghionescu, Alina, Delia Popa, Codruta, Nichita, Norica, Coriu, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429477/ http://dx.doi.org/10.1097/01.HS9.0000976284.94968.31

Ejemplares similares

Modulation of the unfolded protein response by the human hepatitis B virus
por: Lazar, Catalin, et al.
Publicado: (2014)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

PB2332: CLINICAL CHARACTERISTICS AND OUTCOMES OF HIV-ASSOCIATED AGGRESSIVE B-CELL NHL IN CHINA
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Probing the Hepatitis B Virus E-Antigen with a Nanopore Sensor Based on Collisional Events Analysis
por: Bucataru, Ioana C., et al.
Publicado: (2022)

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
por: Chu, Yaya, et al.
Publicado: (2022)

Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL).
por: Dorey, E. L., et al.
Publicado: (1989)

N-Glycosylation and N-Glycan Processing in HBV Biology and Pathogenesis
por: Dobrica, Mihaela-Olivia, et al.
Publicado: (2020)

Targeting Asparagine and Serine Metabolism in Germinal Centre-Derived B Cells Non-Hodgkin Lymphomas (B-NHL)
por: Eraslan, Zuhal, et al.
Publicado: (2021)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Activation of ERAD Pathway by Human Hepatitis B Virus Modulates Viral and Subviral Particle Production
por: Lazar, Catalin, et al.
Publicado: (2012)

Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol.
por: Atra, A., et al.
Publicado: (1998)

PB2277: PROGNOSTIC SIGNIFICANCE OF SERUM MONOCLONAL PROTEINS BASED ON IMMUNOFIXATION ELECTROPHORESIS IN B CELL NON-HODGKIN LYMPHOMA
por: Gao, Yuyang, et al.
Publicado: (2023)

UPR-Mediated Membrane Biogenesis in B Cells
por: Brewer, Joseph W., et al.
Publicado: (2012)

Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset
por: Wang, Tingyan, et al.
Publicado: (2022)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

Challenges and Prospects of Plant-Derived Oral Vaccines against Hepatitis B and C Viruses
por: Pantazica, Ana-Maria Madalina, et al.
Publicado: (2021)

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
por: Wang, Sophia S., et al.
Publicado: (2022)

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol
por: Atra, A, et al.
Publicado: (2000)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
por: Ghogale, Sitaram, et al.
Publicado: (2023)

2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
por: Alkhazraji, Sondus, et al.
Publicado: (2018)

PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA
por: Li, S., et al.
Publicado: (2022)

Association of the LILRA3 Deletion with B-NHL and Functional Characterization of the Immunostimulatory Molecule
por: Low, Hui Zhi, et al.
Publicado: (2013)

The Significance of CD20 Intensity Variance in Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
por: Serbanica, Andreea Nicoleta, et al.
Publicado: (2023)

Anti-Spike (S) Antibody Production Post Covid-19 Vaccination after B Cell Depleting Therapy (BCDT) for Non-Hodgkin Lymphoma (NHL)
por: Molina, Josselyn Glamyr
Publicado: (2021)

PB2548: COMPARISON BETWEEN WEEKLY INTRAVENOUS VERSUS DAILY ORAL VITAMIN B12 SUPPLEMENTATION IN ANEMIA WITH VITAMIN B12 DEFICIENCY
por: Modak, Ketan, et al.
Publicado: (2023)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Characteristics and Outcomes of COVID-19 Patients with Mature B-Cell Non-Hodgkin Lymphomas (mB-Cell NHL): A US Nationwide Electronic Health Record (EHR) Database Study
por: Yue, Xiaomeng, et al.
Publicado: (2021)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

2393. Factors Associated with Time to COVID-19 Vaccination among People with HIV
por: Paz, Aasith Villavicencio, et al.
Publicado: (2023)

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
por: Sehn, L. H., et al.
Publicado: (2022)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2311: EFFICACY EVALUATION AND SAFETY ANALYSIS OF ZANUBRUTINI B COMBINED WITH CHEMOTHERAPY FOR 17 CASES OF RELAPSED REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Chen, Qingfeng, et al.
Publicado: (2023)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.
por: Tzenou, T., et al.
Publicado: (2022)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0a8fbvpnqa9qm8l1r4ds296ufa